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Aripiprazole and haloperidol activate GSK3β-dependent signalling
pathway differentially in various brain regions of rats
Abstract

Aripiprazole, a dopamine D2 receptor (D2R) partial agonist, possesses a unique clinical profile. Glycogen
synthase kinase 3β (GSK3β)-dependent signalling pathways have been implicated in the pathophysiology of
schizophrenia and antipsychotic drug actions. The present study examined whether aripiprazole differentially
affects the GSK3β-dependent signalling pathways in the prefrontal cortex (PFC), nucleus accumbens (NAc),
and caudate putamen (CPu), in comparison with haloperidol (a D2R antagonist) and bifeprunox (a D2R
partial agonist). Rats were orally administrated aripiprazole (0.75 mg/kg), bifeprunox (0.8 mg/kg),
haloperidol (0.1 mg/kg) or vehicle three times per day for one week. The levels of protein kinase B (Akt), pAkt, GSK3β, p-GSK3β, dishevelled (Dvl)-3, and β-catenin were measured by Western Blots. Aripiprazole
increased GSK3β phosphorylation in the PFC and NAc, respectively, while haloperidol elevated it in the NAc
only. However, Akt activity was not changed by any of these drugs. Additionally, both aripiprazole and
haloperidol, but not bifeprunox, increased the expression of Dvl-3 and β-catenin in the NAc. The present
study suggests that activation of GSK3β phosphorylation in the PFC and NAc may be involved in the clinical
profile of aripiprazole; additionally, aripiprazole can increase GSK3β phosphorylation via the Dvl-GSK3β-βcatenin signalling pathway in the NAc, probably due to its relatively low intrinsic activity at D2Rs.
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Abstract: Aripiprazole, a dopamine D2 receptor (D2 R) partial agonist, possesses a unique clinical
profile. Glycogen synthase kinase 3β (GSK3β)-dependent signalling pathways have been implicated
in the pathophysiology of schizophrenia and antipsychotic drug actions. The present study examined
whether aripiprazole differentially affects the GSK3β-dependent signalling pathways in the prefrontal
cortex (PFC), nucleus accumbens (NAc), and caudate putamen (CPu), in comparison with haloperidol
(a D2 R antagonist) and bifeprunox (a D2 R partial agonist). Rats were orally administrated aripiprazole
(0.75 mg/kg), bifeprunox (0.8 mg/kg), haloperidol (0.1 mg/kg) or vehicle three times per day for
one week. The levels of protein kinase B (Akt), p-Akt, GSK3β, p-GSK3β, dishevelled (Dvl)-3,
and β-catenin were measured by Western Blots. Aripiprazole increased GSK3β phosphorylation
in the PFC and NAc, respectively, while haloperidol elevated it in the NAc only. However, Akt
activity was not changed by any of these drugs. Additionally, both aripiprazole and haloperidol,
but not bifeprunox, increased the expression of Dvl-3 and β-catenin in the NAc. The present study
suggests that activation of GSK3β phosphorylation in the PFC and NAc may be involved in the
clinical profile of aripiprazole; additionally, aripiprazole can increase GSK3β phosphorylation via
the Dvl-GSK3β-β-catenin signalling pathway in the NAc, probably due to its relatively low intrinsic
activity at D2 Rs.
Keywords: antipsychotics; aripiprazole; β-catenin; bifeprunox; Dvl-3; GSK3β; haloperidol

1. Introduction
Aripiprazole is an atypical antipsychotic drug with therapeutic effects on both positive and
negative symptoms of schizophrenia, but reduced extrapyramidal side-effects (EPS) compared with
typical antipsychotics (e.g., haloperidol) [1]. The exact mechanisms of aripiprazole remain unclear.
Glycogen synthase kinase 3β (GSK3β) has been implicated in the pathophysiology of schizophrenia
and the actions of antipsychotic drugs [2]. GSK3β is a major downstream regulator of dopamine D2
receptors (D2 Rs), which is targeted by most antipsychotics (including aripiprazole) [3]. Activation
of D2 Rs facilitates the formation of the β-arrestin2-protein phosphatase 2A-protein kinase B (PKB or
Akt) complex, resulting in dephosphorylation of Akt (inactivation), followed by dephosphorylation
(activation) of GSK3β [4–6]. Aripiprazole has been shown to have effects on regulating the Akt-GSK3β
signalling pathway [2]. For example, Seo et al. [7] have revealed that aripiprazole altered GSK3β
activity in the frontal cortex. However, whether aripiprazole can affect GSK3β activity in other
schizophrenia-related brain regions has not yet been studied. Our previous acute study [8] has
found that acute administration of aripiprazole increased the phosphorylation levels of GSK3β in
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indicates that inhibition of GSK3β function in the NAc may contribute to the effects of antipsychotics
on the positive symptoms of schizophrenia.
It is worth noting that Akt did not change in parallel with GSK3β, which is not consistent
with previous reports [12,21,25]. This might be explained by following reasons. First, Roh et al. [25]
have reported that the phosphorylation of Akt induced by antipsychotics were much shorter in
duration than those of GSK3β. In the present study, the animals were sacrificed several hours after
the last administration. Therefore, the phosphorylation levels of Akt might have already decreased to
undetectable levels. This might be the major reason that we only observed the altered p-GSK3β levels,
but not p-Akt. Second, there are two phosphorylating sites of Akt—Thr308 and Ser473, both could
be affected by antipsychotic drug administration [4,21,25–27]. The present study has examined the
Thr308 site of Akt only, since phospho-Thr308-Akt was involved in the D2 Rs-mediated Akt-GSK3β
signalling [4,27]. However, Akt phosphorylated with either site induces phosphorylation of GSK3β
at Ser9 that was examined in the current study. Thereby, it is possible that the elevated p-GSK3β
levels in this study might be induced by phospho-Ser473-Akt from other signalling pathway(s),
and further investigations are needed to study this issue. Lastly, GSK3β is a multi-targeted regulator.
Antipsychotics might affect GSK3β via alternative pathway(s) rather than the D2 Rs-mediated signalling
pathway, such as the Dvl-GSK3β-β-catenin signalling pathway.
We have examined the effects of antipsychotics on the Dvl-GSK3β-β-catenin signalling pathway.
It was observed that both aripiprazole and haloperidol administration increased the expression
of Dvl-3 and β-catenin in accordance with the enhanced phosphorylation of GSK3β in the NAc,
suggesting that antipsychotics is very likely to affect GSK3β activity via Dvl-GSK3β-β-catenin pathway
in this study. However, further studies (e.g., pharmacological or genetic intervention) are required
to confirm this suggestion. In addition, it has been reported that antipsychotics (e.g., aripiprazole,
haloperidol, clozapine, and risperidone) increased the expression of Dvl-3 and/or β-catenin in various
brain regions, including the PFC and striatum [10,12,14]. It is worth noting that the studies by
Alimohamad et al. [12] and Sutton et al. [14] have mixed NAc and CPu together, thus preventing
identification of the sub-region(s) in which the levels of Dvl-3 and β-catenin were increased by
antipsychotic drug administration. This study has separated NAc and CPu, and demonstrated
that antipsychotics affect Dvl-GSK3β-β-catenin signalling specifically in the NAc. Taken together,
it suggested that activation of Dvl-GSK3β-β-catenin signalling in the NAc is a common route, through
which different classes of antipsychotics exert their effects. Lastly, our results do not show any
alteration in the expression of Dvl-3 and β-catenin in the PFC, which is inconsistent with the findings
of previous studies [10,12,14]. The exact reason remains unclear. This may be because the previous
studies [10,12,14] used intramuscular or subcutaneous injection to deliver the drugs, whereas the
current study used oral treatment with different dosages to mimic the clinical situation. Therefore,
whether the effect of antipsychotics on Dvl-GSK3β-β-catenin signalling is treatment method-dependent
requires further validation. Furthermore, one limitation of this study is that the samples have been
investigated by only Western blots method, it is also worthy to further validate these findings using
other methods such as qPCR and immunohistochemistry.
Previously, Min and colleagues [9] have investigated the interaction between the dopaminergic
nervous system and Dvl-GSK3β-β-catenin signalling, and found that only D2 Rs directly affected
β-catenin distribution in the cell nucleus. The present study used aripiprazole, haloperidol and
bifeprunox, all of which have strong affinity with D2 Rs [18,28]. Haloperidol is a potent D2 R antagonist,
whereas aripiprazole and bifeprunox are D2 R partial agonists. Previous studies have revealed that
the intrinsic activity of aripiprazole at D2 Rs is weaker than that of bifeprunox (intrinsic activity at
D2 Rs: aripiprazole vs. bifeprunox vs. dopamine = 86.0% vs. 95.1% vs. 100%) [22,29]. Our results
have demonstrated that administration of both aripiprazole and haloperidol, but not bifeprunox,
had significant effects on altering the expression of Dvl-3 and β-catenin in the NAc. Therefore, first,
blockade of D2 Rs is (indirectly) linked to the activation of the Dvl-GSK3β-β-catenin signalling pathway.
Second, it is very possible that aripiprazole competes with endogenous dopamine in the normal brain
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due to its relatively low intrinsic activity to reduce significantly the activity of endogenous dopamine,
displaying an overall antagonising effect like haloperidol. In contrast, bifeprunox cannot achieve such
effects, probably because of its relatively stronger intrinsic activity at D2 Rs. Taken together, our study
suggests that a relatively low intrinsic activity at D2 Rs might be essential for a D2 R partial agonist to
achieve meaningful effects via affecting the Dvl-GSK3β-β-catenin signalling pathway.
4. Materials and Methods
4.1. Animals and Drug Administration
Male Sprague–Dawley rats (aged eight weeks) were obtained from the Animal Resource Centre
(Perth, Australia). After arrival, all rats were housed in individual cages under environmentally
controlled conditions (temperature 22 ˝ C, light cycle from 07:00 a.m. to 07:00 p.m.), with ad libitum
access to water and a standard laboratory chow diet. All experimental procedures were approved
by the Animal Ethics Committee (Application #AE11/02, 02/2011), University of Wollongong, and
complied with the Australian Code of Practice for the Care and Use of Animals for Scientific Purposes
(2004). All efforts were made to minimise animal distress and prevent suffering.
Before drug administration commenced, the rats were trained for self-administration of the cookie
dough pellets without drugs. After 1-week training, rats were randomly assigned into one of the
following four groups (n = 6/group): aripiprazole (0.75 mg/kg, t.i.d. (ter in die), Otsuka, Tokyo,
Japan); bifeprunox (0.8 mg/kg, t.i.d., Otava, Kiev, Ukraine); haloperidol (0.1 mg/kg, t.i.d., Sigma,
Castle Hill, Australia); or vehicle for one week. Rats were offered cookies with drugs three times a
day (at 06:00 a.m., 02:00 p.m. and 10:00 p.m.) and observed to ensure complete consumption of each
pellet. The dosages were translated from recommended clinical dosages based on body surface area
according to the FDA guidelines [30,31]. This drug administration method has been well established
in our laboratory [32,33]. Specifically, a 0.75 mg/kg aripiprazole, 0.8 mg/kg bifeprunox and 0.1 mg/kg
haloperidol dosage in rats is equivalent to ~7.5, ~8, and ~1 mg in humans (60 kg body weight),
respectively, all of which are within the used/recommended clinical dosages [34–36]. It is worth
noting that aripiprazole and bifeprunox induced over 90% D2 receptor occupancy in rat brains at these
dosages [18], and haloperidol reached approximately 70% occupancy [37], all of which can display
physiological and behavioural effects in rodents, without inducing EPS side-effects [18,38–40]. After
one-week drug administration, all rats were sacrificed between 10:00 a.m. and 12:00 p.m. to minimise
possible circadian-induced variation of protein expression. All animals were euthanised by using
carbon dioxide. Brains were immediately dissected, frozen in liquid nitrogen and stored at ´80 ˝ C
until further use.
4.2. Micro-Dissection of Brain Samples
Following a standard procedure used in our group [8], discrete brain regions were collected using
brain microdissection puncture according to the brain atlas [41]. Briefly, three sections through the
forebrain (Bregma 3.30 to 4.20 mm) were collected for the PFC; and three sections through the striatum
(Bregma 1.00 to 2.20 mm) were collected for the CPu and NAc, respectively. Tissue dissected was kept
at ´80 ˝ C.
4.3. Western Blots
The Western blot experiments were performed following standard procedures repeated in
our previous studies [8,33]. Briefly, frozen tissue was homogenised with 9.8 mL NP-40 cell
lysis buffer (Invitrogen, Camarillo, CA, USA) containing 100 µL Protease Inhibitor Cocktail
(Sigma-Aldrich, St. Louis, MO, USA), 100 µL β-Glycerophosphate (Invitrogen) and 33.3 µL
phenylmethylsulfonylfluoride (Sigma-Aldrich). The homogenised samples were centrifuged, and
the supernatants were collected. Protein concentration of each homogenising solution was measured
by using the DC Protein Assay (Bio-Rad, #500-0111). After denaturing proteins, samples containing
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10 µg of protein were loaded into 4%–20% Criterion™ TGX™ Precast Gels (Bio-Rad, Hercules, CA,
USA, #5671095) in a Criterion™ Vertical Electrophoresis Cell (Bio-rad, #1656001) at 200 V voltage
for 50 min, and then transferred electrophoretically to a polyvinylidene difluoride membrane in a
Criterion™ Blotter (Bio-rad, #1704071) at 100 V voltage for 60 min. All membranes were blocked by
5% bovine serum albumin (BSA) for 60 min and incubated in primary antibodies (diluted in 1% BSA)
over night. Amersham Hyperfilm ECL (GE Healthcare, Chicago, IL, USA, #28-9068-36) and Luminata
Classico Western HRP substrate (Millipore, Billerica, MA, USA, #WBLUC0500) were used to visualise
the immunoreactive bands. The immunoreactive signals were quantified using Bio-Rad Quantity One
software. The data of each targeted protein were then corrected based on their corresponding actin
levels. Experiments were performed in duplicate to ensure consistency.
The antibodies used in the present study to examine the GSK3β-involved pathways were
anti-Akt (1:2000; Cell Signalling, Danvers, MA, USA, #4691), anti-phosphor-Akt (Thr308) (1:1000;
Cell Signalling, #13038), anti-GSK3β (1:2000; Cell Signalling, #5676), anti-phospho-GSK3β (Ser9)
(1:1000; Cell Signalling, #9322), anti-Dvl-3 (1:1000; Santa Cruz Biotechnology, Dallas, TX, USA,
#SC-8027) and anti-β-catenin (1:1000; Santa Cruz Biotechnology, #SC-7963). Mouse anti-actin primary
polyclonal antibody (1:10000; Millipore, #MAB1501) was used to determine the actin levels. The
secondary antibodies were HRP-conjugated anti-rabbit IgG antibody (1:3000; Cell Signalling, #7074)
and HRP-conjugated anti-mouse IgG antibody (1:3000; Cell Signalling, #7076).
4.4. Statistics
All data was analysed using SPSS Statistics V22.0 program (IBM, New York, NY, USA). Data
normality was tested using histograms and a Kolmogorov–Smirnov Z test. For statistical evaluation,
one-way analysis of variance (ANOVA) was performed if the data was normally distributed.
The post hoc Dunnett t test was then conducted to compare each drug treatment group with the
control group. The results of Western blots were normalised by taking the average value of the control
group as 100%. The phosphorylation to total signal was calculated using the data from the same
blot. Pearson’s correlation test was used to analyse the relationships. A p-value of less than 0.05 was
considered as statistically significant.
5. Conclusions
The present study explored the in vivo effects of one-week oral administration of aripiprazole on
the GSK3β-dependent signalling pathways in three brain regions that are associated with schizophrenia
and the actions of antipsychotics, in comparison with haloperidol and bifeprunox. The current study
provides in vivo evidence that inhibition of GSK3β activity in the PFC and NAc might be linked to
the clinical profile of aripiprazole. This study further suggests that, like haloperidol, aripiprazole
can activate Dvl-GSK3β-β-catenin signalling in the NAc, which is probably due to the relatively low
intrinsic activity at D2 Rs.
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